

Positive Tuberculin Skin Test/IGRA Report

If active TB is suspected, please notify the Health Unit immediately at 705-474-1400 or 1-800-563-2808 ext. 5229

Client Demographics				
Name:		Current Address:		
Date of Birth:		City:		
☐ Male ☐ Female ☐ Other:		Prov:		
Health Card Number:		Postal Code:		
Email address:		Canadian Aboriginal: Yes No		
Telephone:		Country of birth:		
		Year Arrived in Canada	:	
Tuberculin Skin Testing (TST) - Under the HPPA, all positive TSTs are to be reported to the Medical Officer of Health within 7 days; please fax this form to 705-482-0670 .				
Reason for testing: School Work Volunteer Other (Specify):				
O		(yyyy-mm-dd)	Result (mm of induration)	
Will state of the		Will say	,	
Previous TST: Yes No Unknown Date: Result:				
History of BCG vaccine: ☐ Yes ☐ No ☐ Unknown If yes, age when received: Scar seen: ☐ Yes ☐ No ☐ Unknown				
Medical Assessment				
IGRA testing done: Yes No If yes, result: (please include a copy of the report)				
HIV testing done: Yes No If yes, result:				
TB Symptoms with onset				
Symptomatic: ☐ Yes ☐ No Check all that apply: ☐ Productive cough ☐ Non-productive cough ☐ Fever				
□ Night sweats □ Hemoptysis □ Fatigue □ Anorexia □ Weight loss - Other				
Chest x-ray				
Chest x-ray requisition given: Yes No Date:				
Follow-up				
Referred to client's health care provider $\ \square$ Yes $\ \square$ No		Name:		
Referred to specialist \square Yes \square No		Name:		
Reported by:		Facility/Healthcare Office Name:		
Phone Number:		Fax:		
Signature:		Date:		
For HCP or specialist to complete - Sputum and chest x-ray – please fax results once available to 705-482-0670				
□ N/A □ Ordered		#1 collected on (yyyy/	•	
		#2 collected on (yyyy/	· · · · ·	
		#3 collected on (yyyy/mm/dd):		
Will LTBI treatment be initiated?		No, specify reason:		
Please see next page for risk factors to consider		•	y of the prescription to 705-482-0670 ,	
		medications to treat L	TBI are free from the Health Unit.	



Please consider the following risk factors when considering LTBI treatment. The following website can also be used as an aid in interpreting TST results: http://www.tstin3d.com/index.html

Risk factors for developing active TB for those infected with Mycobacterium tuberculosis

Very High Risk	People living with Human Immunodeficiency Virus (HIV)
	Child or adolescent (<18 y) tuberculosis contact
	Adult (≥ 18 y) tuberculosis contact
	Silicosis
High Risk	Stage 4 or 5 chronic kidney disease with or without dialysis
	Transplant recipients (solid organ or hematopoietic)
	Fibronodular disease
	Receiving immunosuppressing drugs (e.g., tumor necrosis factor alpha inhibitors or
	steroids) ^a
	Cancer (lung, sarcoma, leukemia, lymphoma or gastrointestinal)
Moderate Risk	Granuloma on chest x-ray
	Diabetes
	Heavy alcohol use (at least 3 drinks/day)
Low Risk	General (adult) population with no known risk factor
	Persons with a positive two-step TST booster and no known risk factor

^aRisk does not appear significantly elevated with low-dose steroids (i.e., prednisone), but elevated with moderate or high dose (low dose: ≤ 9mg/day; medium dose: 10-19mg/day; and high dose: ≥20mg/day).

(Campbell et al., 2022)

"This information is being collected pursuant to the Health Protection and Promotion Act, R.S.O.1990, c.H.7 and will be retained, used, disclosed, and disposed of in accordance with the Municipal Freedom of Information and Protection of Privacy Act, R.S.O. 1990, c.M.56, the Personal Health Information Protection Act, 2004, S.O.c.3 and all applicable federal and provincial legislation and regulations governing the collection, retention, use, disclosure, and disposal of information. Any questions regarding this collection may be directed to the Personal Health Information Manager at the North Bay Parry Sound District Health Unit, 345 Oak St. W., North Bay, ON P1B 2T2, 705-474-1400 / 1-800-563-2808 or at privacy@healthunit.ca."

References

Jonathon R. Campbell, Christopher Pease, Peter Daley, Madhukar Pai & Dick Menzies. (2022). Chapter 4: Diagnosis of tuberculosis infection, Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 6:sup1, 49-65, DOI: 10.1080/24745332.2022.2036503

